New cocktail of drugs shows promise for tough prostate cancer
NCT ID NCT02913196
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tested a combination of four drugs—apalutamide, abiraterone, docetaxel, and prednisone—in 16 men with metastatic castrate-resistant prostate cancer, a form of the disease that no longer responds to standard hormone therapy. The main goal was to find a safe dose of apalutamide when given with the other drugs. Researchers also tracked changes in PSA levels and tumor growth. Because this is a phase 1 study, it primarily looks at safety and dosing, not yet at how well the treatment works.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
apalutamide, abiraterone acetate, docetaxel, and prednisone
What this could lead to
If successful, this could lead to a more effective treatment option for men with advanced prostate cancer that has stopped responding to standard hormone therapy.
What could go wrong
This is a very early phase 1 trial with only 16 participants, focused on safety and dosing. The combination may cause significant side effects, and it is unknown if it will improve survival or quality of life.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER METASTATIC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
GU Research Network/Urology Cancer Center
Omaha, Nebraska, 68130, United States
-
Weill Cornell Medical College
New York, New York, 10065, United States